ASTRA:CRYPTOCAPMarket Cap ASTRA, $ Analysis

AstraZeneca is trading at $187.03, just above its 20‑day SMA (185.0) but still below the 50‑day SMA (191.2), indicating a modest upward bias. The RSI sits at 48.5, suggesting the stock is neither overbought nor oversold, while the MACD histogram is positive and the signal line turned bullish, offering a technical nudge to the upside despite a decreasing volume trend and a 30‑day volatility of about 21%. Recent earnings beat and upgraded guidance have lifted sentiment, reflected in the “Extreme Greed” market mood (FGI 91.6) and a strong analyst consensus (10 analysts, “strong_buy”).
Fundamentally, AZN posted 12.5% revenue growth, robust 81.5% gross margin and a 27.9% operating margin, with forward EPS projected at $8.02. The dividend yield of 1.69% is covered by a 48% payout ratio and solid free cash flow, supporting sustainability. However, the DCF fair‑value estimate of $75.9 places the current price well above intrinsic value, flagging an overvaluation despite a 20% upside potential relative to the current level. Low beta (≈0.22‑0.53) and a defensive healthcare sector temper risk, while global exposure and ongoing regulatory pipelines add moderate regulatory and geographic considerations.